FDA Grants Regular Approval to Rubraca for Metastatic Castration-Resistant Prostate Cancer

Originally published by our sister publication Clinical Oncology NewsBy Clinical Oncology News StaffThe FDA approved rucaparib (Rubraca, pharmaand GmbH) for adults with a deleterious BRCA mutation (BRCAm) (germline and/or somatic)–associated metastatic castration-resistant prostate cancer (mCRPC) previously treated with an androgen receptor–directed therapy. Patients should be selected for therapy using an FDA-approved companion diagnostic. Rucaparib was granted accelerated approval